Gene Therapy Clinical Trials
Risk-Group Classification of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
This clinical trial is studying risk-group classification of patients with newly diagnosed acute lymphoblastic leukemia. Developing a risk-group classification guide may help doctors assign patients with newly diagnosed acute lymphoblastic leukemia to treatment clinical trials.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: laboratory biomarker analysis
Eligibility
Inclusion Criteria:
- Newly diagnosed acute lymphoblastic leukemia, defined by any of the following:
- At least 25% blasts in the bone marrow
- Absolute blast count at least 10,000/mm^3, if bone marrow aspiration is not
performed
- No prior registration on this study
Ages Eligible for Study
1 Year - 30 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting